NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus)

Pancreas

Volumn 39, Issue 6, 2010, Pages 784-798

  Phan, Alexandria T ^a   Öberg, Kjell ^b   Choi, Junsung ^c   Harrison Jr , Lynn H ^d   Hassan, Manal M ^a   Strosberg, Jonathan R ^c   Krenning, Eric P ^e   Kocha, Walter ^f   Woltering, Eugene A ^g   Maples, William J ^h  

^a UNIVERSITY OF TEXAS   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Baptist Health South Florida ^*  (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN CARBON 11; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANGIOPEPTIN; ANTIDIARRHEAL AGENT; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; CORTICOSTEROID; CYPROHEPTADINE; DEXAMETHASONE; DOPAMINE; INTERFERON; KETANSERIN; KETOCONAZOLE; METHYSERGIDE; NICOTINAMIDE; NICOTINIC ACID; OCTREOTIDE; ONDANSETRON; PENTETREOTIDE; PHENYLEPHRINE; PLASMA SUBSTITUTE; SEROTONIN ANTAGONIST; SOMATOSTATIN DERIVATIVE; TECHNETIUM 99M; TEMOZOLOMIDE; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN;

ACROMEGALY; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; BRONCHOSPASM; BRONCHUS CARCINOID; BRONCHUS TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOID SYNDROME; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; CUSHING SYNDROME; CYTOREDUCTIVE SURGERY; DEPRESSION; DIAGNOSTIC IMAGING; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ENDOSCOPIC SURGERY; FATIGUE; FLU LIKE SYNDROME; FLUSHING; FOLLOW UP; GYNECOMASTIA; HISTOPATHOLOGY; HUMAN; HYPOTENSION; IMPOTENCE; LARGE CELL CARCINOMA; LEUKOPENIA; LIBIDO DISORDER; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LUNG SCINTISCANNING; LUNG SMALL CELL CANCER; LUNG TUMOR; MEDICAL SOCIETY; MENSTRUAL IRREGULARITY; MENTAL DISEASE; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; NAUSEA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PELLAGRA; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR AFFINITY; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX RADIOGRAPHY; THORAX SCINTISCANNING; THORAX TUMOR; THROMBOCYTOPENIA; THYMOMA; THYMUS SURGERY; TUMOR CLASSIFICATION; UNITED STATES; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

HUMANS; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; THORAX; THYMUS NEOPLASMS;

EID: 77955216385     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181ec1380     Document Type: Review

References (113)

1. Oberndorfer S. Karzinoide tumoren des dunndarms. Frankf Z Pathol. 1907;1:425-429.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after Bcarcinoid[: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18): 3063-3072.
3. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer. 2005;5(5):367-375.
4. Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A. 1976;84(4):322-330.
5. Godwin JD 2nd. Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975;36(2):560-569.
6. Hemminki K, Li X. Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer. 2001;94(3):444-448.
7. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934-959.
8. Shimosato Y, Mukai K. Tumors of the Mediastinum. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1995.
9. Kayser K, Kayser C, Rahn W, et al. Carcinoid tumors of the lung: immuno- and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically. J Surg Oncol. 1996;63(2):99-106.
10. Erasmus JJ, McAdams HP, Patz EF Jr, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol. 1998;170(5):1369-1373.
11. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol. 2000;31(10):1255- 1265.
12. Marx SJ. Multiple endocrine neoplasia type 1. In: Vogelstein B and Kinzler KW, eds. The Genetics Basis of Human Cancer. New York, NY: McGraw Hill; 2002:475-500.
13. Granberg D, Sundin A, Janson ET, et al. Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf). 2003;59(6): 793-799.
14. Nessi R, Basso Ricci P, Basso Ricci S, et al. Bronchial carcinoid tumors: radiologic observations in 49 cases. J Thorac Imaging. 1991;6(2):47-53.
15. Jeung MY, Gasser B, Gangi A, et al. Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings. Radiographics. 2002;22(2):351-365.
16. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;119(6):1647-1651.
17. Kurul IC, Topcu S, Tastepe I, et al. Surgery in bronchial carcinoids: experience with 83 patients. Eur J Cardiothorac Surg. 2002;21(5): 883-887.
18. Divisi D, Crisci R. Carcinoid tumors of the lung and multimodal therapy. Thorac Cardiovasc Surg. 2005;53(3):168-172.
19. Semelka RC, Custodio CM, Cem Balci N, et al. Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging. 2000;11(2):141-148.
20. Pamuklar E, Semelka RC. MR imaging of the pancreas. Magn Reson Imaging Clin N Am. 2005;13(2):313-330.
21. Kelekis NL, Semelka RC. MRI of pancreatic tumors. Eur Radiol. 1997;7(6):875-886.
22. Debray MP, Geoffroy O, Laissy JP, et al. Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol. 2001;74(887):1065-1070.
23. Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol. 2003;180(1):121-128.
24. Yellin A, Zwas ST, Rozenman J, et al. Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr Med Assoc J. 2005;7(11):712-716.
25. Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496-506.
26. Balon HR, Goldsmith SJ, Siegel BA, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med. 2001;42(7):1134-1138.
27. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90(6):3392-3400.
28. Travis WD, Giroux DJ, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2008;3(11): 1213-1223.
29. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48(11):2485-2492.
30. Suster S, Moran CA. Thymic carcinoma: spectrum of differentiation and histologic types. Pathology. 1998;30(2):111-122.
31. SEER Registry. SEER Summary Staging ManualV2007 Codes and Coding Instruction. Bethesda, MD: National Cancer Institute, NIH; 2008.
32. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86(5):858-865.
33. Goebel SU, Serrano J, Yu F, et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer. 1999;85(7): 1470-1483. (Pubitemid 29152818)
34. Bernini GP, Moretti A, Ferdeghini M, et al. A new human chromogranin FA immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer. 2001;84(5):636-642.
35. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 2004;60(5):644-652.
36. Tormey WP, FitzGerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J. 1995;71(839):542-545.
37. Feldman JM, Lee EM. Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr. 1985; 42(4):639-643.
38. Diaz-Jimenez JP, Canela-Cardona M, Maestre-Alcacer J. Nd:YAG laser photoresection of low-grade malignant tumors of the tracheobronchial tree. Chest. 1990;97(4):920-922.
39. Lucchi M, Melfi F, Ribechini A, et al. Sleeve and wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the bronchial airway. J Thorac Cardiovasc Surg. 2007;134(2): 373-377.
40. Skuladottir H, Hirsch FR, Hansen HH, et al. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer. 2002;37(2):127-135.
41. Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer. 2008;113(1):5-21.
42. Ferguson MK, Landreneau RJ, Hazelrigg SR, et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000;18(2):156-161.
43. Thomas CF Jr, Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement. Chest. 2001;119(4):1143-1150.
44. Cardillo G, Sera F, Di Martino M, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg. 2004;77(5):1781-1785.
45. Ducrocq X, Thomas P, Massard G, et al. Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg. 1998;65(5):1410-1414.
46. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24(1):70-76.
47. Soga J, Yakuwa Y. Bronchopulmonary carcinoids: an analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg. 1999;5(4):211-219.
48. Matilla-Gonzalez J, Garcia-Yuste M, Moreno-Mata N, et al. O-179 Typical and atypical carcinoid tumors (NEC grades 1 and 2): prognostic factors in metastases and local recurrence. Lung Cancer. 2005;49(suppl 2):S60.
49. Chughtai TS, Morin JE, Sheiner NM, et al. Bronchial carcinoidVtwenty years' experience defines a selective surgical approach. Surgery. 1997;122(4):801-808.
50. Harpole DH Jr, Feldman JM, Buchanan S, et al. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg. 1992;54(1):50-54; discussion 54-55.
51. Fiala P, Petraskova K, Cernohorsky S, et al. Bronchial carcinoid tumors: long-term outcome after surgery. Neoplasma. 2003;50(1): 60-65.
52. Martini N. The role of surgery in N1 and N2 lung cancer. Front Radiat Ther Oncol. 1994;28:92-101.
53. Fukai I, Masaoka A, Fujii Y, et al. Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients. Ann Thorac Surg. 1999;67(1):208-211.
54. de Montpreville VT, Macchiarini P, Dulmet E. Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases. J Thorac Cardiovasc Surg. 1996;111(1):134-141.
55. Saltz L. Neuroendocrine tumorsVcarcinoid tumors. In: NCCN Clinical Practice Guidelines in Oncology. 2009 Available at http:// www.nccn.org/ professionals/physician-gls/PDF/neuroendocrine.pdf.
56. Feldman JM. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem. 1986;32(5):840-844.
57. Feldman JM. Carcinoid tumors and syndrome. Semin Oncol. 1987;14(3):237-246.
58. Sjoblom SM. Clinical presentation and prognosis of gastrointestinal carcinoid tumours. Scand J Gastroenterol. 1988;23(7):779-787.
59. Ferrari L, Seregni E, Martinetti A, et al. Chromogranin A measurement in neuroendocrine tumors. Int J Biol Markers. 1998;13(1):3-9.
60. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25(15): 1967-1973.
61. Weingarten TN, Abel MD, Connolly HM, et al. Intraoperative management of patients with carcinoid heart disease having valvular surgery: a review of one hundred consecutive cases. Anesth Analg. 2007;105(5):1192-1199.
62. Parris WC, Oates JA, Kambam J, et al. Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome. Can J Anaesth. 1988;35(4):413-416.
63. Quinlivan JK, Roberts WA. Intraoperative octreotide for refractory carcinoid-induced bronchospasm. Anesth Analg. 1994;78(2): 400-402.
64. Orbach-Zinger S, Lombroso R, Eidelman LA. Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide. Can J Anaesth. 2002;49(7):678-681.
65. Harris AG, O'Dorisio TM, Woltering EA, et al. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci. 1995; 40(7):1464-1473.
66. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600-606.
67. Woltering EA, Mamikunian PM, Zietz S, et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas. 2005;31(4):392-400.
68. Anthony L, Stafford S, Cronin M. Octreotide LAR doses used in clinical practice: Results from an internet survey and a clinical practice. In: Gary A, ed. Annual Meeting of the American Society of Clinical Oncology; June 5, 2005.
69. Smith DB, Scarffe JH, Wagstaff J, et al. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep. 1987;71(12):1265-1266.
70. Creutzfeldt W, Bartsch HH, Jacubaschke U, et al. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. Acta Oncol. 1991;30(4):529-535.
71. Doberauer C, Mengelkoch B, Kloke O, et al. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha. Acta Oncol. 1991;30(5):603-605.
72. Biesma B, Willemse PH, Mulder NH, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer. 1992;66(5):850-855.
73. Janson ET, Ronnblom L, Ahlstrom H, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol. 1992;3(8):635-638.
74. Oberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol. 1992;3(1):35-41.
75. Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer. 1993;72(10):3099-3105.
76. Di Bartolomeo M, Bajetta E, Di Zilembo N, et al. Treatment of carcinoid syndrome with recombinant interferon alpha-2a. Acta Oncol. 1993;32(2):235-238.
77. Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs. 1994;5(5):503-519.
78. Dirix LY, Vermeulen PB, Fierens H, et al. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumorsVan antiangiogenic effect? Anticancer Drugs. 1996;7(2):175-181.
79. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001;12(suppl 2):S111-114.
80. Shah T, Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19(4):617-636.
81. Plockinger U, Couvelard A, Falconi M, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology. 2008;87(1):20-30. (Pubitemid 350308291)
82. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32(2):225-229.
83. Frank M, Klose KJ,Wied M, et al. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol. 1999; 94(5):1381-1387.
84. Anderson JV, Coupe MO, Morris JA, et al. Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist. Br Med J (Clin Res Ed). 1987;294(6580):1129.
85. Coupe M, Levi S, Ellis M, et al. Therapy for symptoms in the carcinoid syndrome. Q J Med. 1989;73(271):1021-1036.
86. Jacobsen MB. Ondansetron in carcinoid syndrome. Lancet. 1992;340(8812):185.
87. Platt AJ, Heddle RM, Rake MO, et al. Ondansetron in carcinoid syndrome. Lancet. 1992;339(8806):1416.
88. von der Ohe MR, Camilleri M, Kvols LK, et al. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med. 1993;329(15):1073-1078.
89. Wymenga AN, de Vries EG, Leijsma MK, et al. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur J Cancer. 1998;34(8):1293-1294.
90. Jones JE, Shane SR, Gilbert E, et al. Cushing's syndrome induced by the ectopic production of ACTH by a bronchial carcinoid. J Clin Endocrinol Metab. 1969;29(1):1-5.
91. DeStephano DB, Lloyd RV, Schteingart DE. Cushing's syndrome produced by a bronchial carcinoid tumor. Hum Pathol. 1984; 15(9):890-892.
92. Limper AH, Carpenter PC, Scheithauer B, et al. The Cushing syndrome induced by bronchial carcinoid tumors. Ann Intern Med. 1992;117(3):209-214.
93. Scanagatta P, Montresor E, Pergher S, et al. Cushing's syndrome induced by bronchopulmonary carcinoid tumours: a review of 98 cases and our experience of two cases. Chir Ital. 2004;56(1):63-70.
94. Scheithauer BW, Carpenter PC, Bloch B, et al. Ectopic secretion of a growth hormoneYreleasing factor. Report of a case of acromegaly with bronchial carcinoid tumor. Am J Med. 1984;76(4):605-616.
95. Carroll DG, Delahunt JW, Teague CA, et al. Resolution of acromegaly after removal of a bronchial carcinoid shown to secrete growth hormone releasing factor. Aust N Z J Med. 1987;17(1):63-67.
96. Filosso PL, Donati G, Rena O, et al. Acromegaly as manifestation of a bronchial carcinoid tumour. Asian Cardiovasc Thorac Ann. 2003;11(2):189.
97. Athanassiadi K, Exarchos D, Tsagarakis S, et al. Acromegaly caused by ectopic growth hormoneYreleasing hormone secretion by a carcinoid bronchial tumor: a rare entity. J Thorac Cardiovasc Surg. 2004;128(4):631-632.
98. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656- 4663.
99. Schnirer II, Yao JC, Ajani JA. CarcinoidVa comprehensive review. Acta Oncol. 2003;42(7):672-692.
100. Kolby L, Persson G, Franzen S, et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90(6): 687-693.
101. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumorsVthe International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21(14):2689-2696.
102. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13(10):2986-2991.
103. Maroun J, Kocha W, Kvols L, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol. 2006;13(2):67-76.
104. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg. 2001;25(6):693-696.
105. Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2008;66(3):493-500.
106. Pommier RF, Vetto JT, Lee JT, et al. Synchronous nonYsmall cell lung cancers. Am J Surg. 1996;171(5):521-524.
107. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104(8):1590-1602.
108. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271-279.
109. Dezarn WA. Quality assurance issues for therapeutic application of radioactive microspheres. Int J Radiat Oncol Biol Phys. 2008; 71(suppl 1):S147-S151.
110. Rhee TK, Lewandowski RJ, Liu DM, et al. 90- Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247(6):1029-1035.
111. Kalinowski M, Dressler M, Konig A, et al. Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009;79(3):137-142.
112. Jones A, Alexander HR Jr. Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies. Surg Oncol Clin N Am. 2008;17(4):857-876, x.
113. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169(1): 36-42; discussion 42-43.